Revvity [RVTY] vs Idexx Laboratories [IDXX] Detailed Stock Comparison
Revvity
NYSE
Loading...
Idexx Laboratories
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Revvity wins in 8 metrics, Idexx Laboratories wins in 11 metrics, with 0 ties. Idexx Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Revvity | Idexx Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 38.65 | 54.48 | Revvity |
| Price-to-Book Ratio | 1.38 | 36.01 | Revvity |
| Debt-to-Equity Ratio | 44.66 | 84.81 | Revvity |
| PEG Ratio | 17.23 | 54.80 | Revvity |
| EV/EBITDA | 15.19 | 38.11 | Revvity |
| Profit Margin (TTM) | 10.19% | 24.41% | Idexx Laboratories |
| Operating Margin (TTM) | 14.49% | 33.62% | Idexx Laboratories |
| EBITDA Margin (TTM) | 14.49% | 33.62% | Idexx Laboratories |
| Return on Equity | 3.61% | 64.87% | Idexx Laboratories |
| Return on Assets (TTM) | 2.07% | 23.26% | Idexx Laboratories |
| Free Cash Flow (TTM) | $541.65M | $798.08M | Idexx Laboratories |
| Dividend Yield | 0.30% | N/A | N/A |
| 1-Year Return | -26.87% | 36.29% | Idexx Laboratories |
| Price-to-Sales Ratio (TTM) | 3.74 | 12.99 | Revvity |
| Enterprise Value | $12.76B | $53.08B | Idexx Laboratories |
| EV/Revenue Ratio | 4.56 | 13.15 | Revvity |
| Gross Profit Margin (TTM) | 56.49% | 62.62% | Idexx Laboratories |
| Revenue per Share (TTM) | $23 | $50 | Idexx Laboratories |
| Earnings per Share (Diluted) | $2.30 | $12.03 | Idexx Laboratories |
| Beta (Stock Volatility) | 0.92 | 1.50 | Revvity |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Revvity vs Idexx Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Revvity | 0.44% | -1.58% | -13.73% | -6.52% | -24.38% | -22.46% |
| Idexx Laboratories | 1.23% | 22.88% | 22.13% | 34.30% | 41.55% | 60.95% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Revvity | -26.87% | -45.01% | -26.56% | 71.89% | 305.04% | 324.65% |
| Idexx Laboratories | 36.29% | 66.00% | 73.45% | 747.91% | 2,238.52% | 4,129.18% |
Performance & Financial Health Analysis: Revvity vs Idexx Laboratories
| Metric | RVTY | IDXX |
|---|---|---|
| Market Information | ||
| Market Cap | $10.48B | $52.43B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 1,834,125 | 1,088,184 |
| 90 Day Avg. Volume | 1,345,435 | 682,031 |
| Last Close | $86.84 | $658.06 |
| 52 Week Range | $85.12 - $129.50 | $356.14 - $688.12 |
| % from 52W High | -32.94% | -4.37% |
| All-Time High | $203.16 (Dec 27, 2021) | $706.95 (Jul 26, 2021) |
| % from All-Time High | -57.26% | -6.92% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.04% | 0.11% |
| Quarterly Earnings Growth | -0.03% | 0.45% |
| Financial Health | ||
| Profit Margin (TTM) | 0.10% | 0.24% |
| Operating Margin (TTM) | 0.14% | 0.34% |
| Return on Equity (TTM) | 0.04% | 0.65% |
| Debt to Equity (MRQ) | 44.66 | 84.81 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $64.29 | $18.20 |
| Cash per Share (MRQ) | $8.44 | $2.06 |
| Operating Cash Flow (TTM) | $584.59M | $905.81M |
| Levered Free Cash Flow (TTM) | $531.58M | $625.74M |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.30% | N/A |
| Last 12-Month Dividend | $0.28 | N/A |
Valuation & Enterprise Metrics Analysis: Revvity vs Idexx Laboratories
| Metric | RVTY | IDXX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 38.65 | 54.48 |
| Forward P/E | 17.23 | 54.80 |
| PEG Ratio | 17.23 | 54.80 |
| Price to Sales (TTM) | 3.74 | 12.99 |
| Price to Book (MRQ) | 1.38 | 36.01 |
| Market Capitalization | ||
| Market Capitalization | $10.48B | $52.43B |
| Enterprise Value | $12.76B | $53.08B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.56 | 13.15 |
| Enterprise to EBITDA | 15.19 | 38.11 |
| Risk & Other Metrics | ||
| Beta | 0.92 | 1.50 |
| Book Value per Share (MRQ) | $64.29 | $18.20 |
Financial Statements Comparison: Revvity vs Idexx Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | RVTY | IDXX |
|---|---|---|
| Revenue/Sales | $664.76M | $998.43M |
| Cost of Goods Sold | $289.22M | $375.05M |
| Gross Profit | $375.55M | $623.38M |
| Research & Development | $53.60M | $59.06M |
| Operating Income (EBIT) | $72.23M | $316.53M |
| EBITDA | $172.95M | $351.81M |
| Pre-Tax Income | $52.38M | $310.08M |
| Income Tax | $10.71M | $67.41M |
| Net Income (Profit) | $42.24M | $242.68M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | RVTY | IDXX |
|---|---|---|
| Cash & Equivalents | $1.14B | $163.97M |
| Total Current Assets | $2.32B | $1.32B |
| Total Current Liabilities | $648.19M | $1.14B |
| Long-Term Debt | $3.33B | $546.80M |
| Total Shareholders Equity | $7.64B | $1.45B |
| Retained Earnings | $5.88B | $5.58B |
| Property, Plant & Equipment | $660.38M | $833.62M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | RVTY | IDXX |
|---|---|---|
| Operating Cash Flow | $172.05M | $235.07M |
| Capital Expenditures | N/A | $-30.03M |
| Free Cash Flow | $112.17M | $207.94M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | $-153.59M | $-400.89M |
Short Interest & Institutional Ownership Analysis
| Metric | RVTY | IDXX |
|---|---|---|
| Shares Short | 6.05M | 2.64M |
| Short Ratio | 5.76 | 5.58 |
| Short % of Float | 0.07% | 0.04% |
| Average Daily Volume (10 Day) | 1,834,125 | 1,088,184 |
| Average Daily Volume (90 Day) | 1,345,435 | 682,031 |
| Shares Outstanding | 120.65M | 81.60M |
| Float Shares | 116.90M | 79.14M |
| % Held by Insiders | 0.00% | 0.01% |
| % Held by Institutions | 0.99% | 1.00% |
Dividend Analysis & Yield Comparison: Revvity vs Idexx Laboratories
| Metric | RVTY | IDXX |
|---|---|---|
| Last 12-Month Dividend | $0.28 | N/A |
| Last 12-Month Dividend Yield | 0.30% | N/A |
| 3-Year Avg Annual Dividend | $0.28 | N/A |
| 3-Year Avg Dividend Yield | 0.06% | N/A |
| 3-Year Total Dividends | $0.84 | N/A |
| Ex-Dividend Date | Apr 17, 2025 | N/A |